$57.32
2.05% (Daily)
Market Cap
$8.23B
Revenue
$N/A
Rank by MCap
#1441
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Grant E. Pickering M.B.A.
Headquarters
San Carlos, CA
Employees
414
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel co...
Loading chart…